Search research articles
Contact Us
Filters
Showing results (71-80 of 127) with videos related to
Page
of 13
Sort By:
European Journal of Cardio-Thoracic Surgery : Official Journal of the European Association for Cardio-Thoracic Surgery
|
June 20, 2015
A difficult decision: what should we do when malignant tumours are diagnosed in patients supported by left ventricular assist devices?
Hassiba Smail, Christian Pfister, Jean-Marc Baste, et al.
European Urology
|
September 2, 2020
Randomized Phase III Trial of Dose-dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin, or Gemcitabine and Cisplatin as Perioperative Chemotherapy for Patients with Muscle-invasive Bladder Cancer. Analysis of the GETUG/AFU V05 VESPER Trial Secondary Endpoints: Chemotherapy Toxicity and Pathological Responses
Christian Pfister, Gwenaelle Gravis, Aude Fléchon, et al.
European Journal of Cancer (Oxford, England : 1990)
|
June 10, 2014
The orexin type 1 receptor is overexpressed in advanced prostate cancer with a neuroendocrine differentiation, and mediates apoptosis
David Alexandre, Coralie Hautot, Marwa Mehio, et al.
The Lancet. Oncology
|
December 24, 2023
Perioperative dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin in muscle-invasive bladder cancer (VESPER): survival endpoints at 5 years in an open-label, randomised, phase 3 study
Christian Pfister, Gwenaelle Gravis, Aude Flechon, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 7, 2022
Dose-Dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin or Gemcitabine and Cisplatin as Perioperative Chemotherapy for Patients With Nonmetastatic Muscle-Invasive Bladder Cancer: Results of the GETUG-AFU V05 VESPER Trial
Christian Pfister, Gwenaelle Gravis, Aude Fléchon, et al.
Cancer
|
October 18, 2007
Cytoreductive nephron-sparing surgery does not appear to undermine disease-specific survival in patients with metastatic renal cell carcinoma
Georg C Hutterer, Jean-Jacques Patard, Marc Colombel, et al.
Progres En Urologie : Journal De L'Association Francaise D'Urologie Et De La Societe Francaise D'Urologie
|
May 27, 2008
["Superficial bladder cancers" do not exist anymore]
J Irani, S Bernardini, J-L Davin, et al.
Cancers
|
March 29, 2023
Refining the Characterization and Outcome of Pathological Complete Responders after Neoadjuvant Chemotherapy for Muscle-Invasive Bladder Cancer: Lessons from the Randomized Phase III VESPER (GETUG-AFU V05) Trial
Stéphane Culine, Valentin Harter, Clémentine Krucker, et al.
BMC Cancer
|
February 19, 2018
Safety and efficacy of temsirolimus as second line treatment for patients with recurrent bladder cancer
Marina Pulido, Guilhem Roubaud, Anne-Laure Cazeau, et al.
Progres En Urologie : Journal De L'Association Francaise D'Urologie Et De La Societe Francaise D'Urologie
|
December 3, 2003
[Upper urinary tract tumor: conservative treatment of localized forms]
Jacques Irani, Fabien Saint, Jean-Louis Bonnal, et al.
Page
of 13
Search research articles
Search
Showing results (71-80 of 127) with videos related to
Sort By:
Page
of 13
European Journal of Cardio-Thoracic Surgery : Official Journal of the European Association for Cardio-Thoracic Surgery
|
June 20, 2015
A difficult decision: what should we do when malignant tumours are diagnosed in patients supported by left ventricular assist devices?
Hassiba Smail, Christian Pfister, Jean-Marc Baste, et al.
European Urology
|
September 2, 2020
Randomized Phase III Trial of Dose-dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin, or Gemcitabine and Cisplatin as Perioperative Chemotherapy for Patients with Muscle-invasive Bladder Cancer. Analysis of the GETUG/AFU V05 VESPER Trial Secondary Endpoints: Chemotherapy Toxicity and Pathological Responses
Christian Pfister, Gwenaelle Gravis, Aude Fléchon, et al.
European Journal of Cancer (Oxford, England : 1990)
|
June 10, 2014
The orexin type 1 receptor is overexpressed in advanced prostate cancer with a neuroendocrine differentiation, and mediates apoptosis
David Alexandre, Coralie Hautot, Marwa Mehio, et al.
The Lancet. Oncology
|
December 24, 2023
Perioperative dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin in muscle-invasive bladder cancer (VESPER): survival endpoints at 5 years in an open-label, randomised, phase 3 study
Christian Pfister, Gwenaelle Gravis, Aude Flechon, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 7, 2022
Dose-Dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin or Gemcitabine and Cisplatin as Perioperative Chemotherapy for Patients With Nonmetastatic Muscle-Invasive Bladder Cancer: Results of the GETUG-AFU V05 VESPER Trial
Christian Pfister, Gwenaelle Gravis, Aude Fléchon, et al.
Cancer
|
October 18, 2007
Cytoreductive nephron-sparing surgery does not appear to undermine disease-specific survival in patients with metastatic renal cell carcinoma
Georg C Hutterer, Jean-Jacques Patard, Marc Colombel, et al.
Progres En Urologie : Journal De L'Association Francaise D'Urologie Et De La Societe Francaise D'Urologie
|
May 27, 2008
["Superficial bladder cancers" do not exist anymore]
J Irani, S Bernardini, J-L Davin, et al.
Cancers
|
March 29, 2023
Refining the Characterization and Outcome of Pathological Complete Responders after Neoadjuvant Chemotherapy for Muscle-Invasive Bladder Cancer: Lessons from the Randomized Phase III VESPER (GETUG-AFU V05) Trial
Stéphane Culine, Valentin Harter, Clémentine Krucker, et al.
BMC Cancer
|
February 19, 2018
Safety and efficacy of temsirolimus as second line treatment for patients with recurrent bladder cancer
Marina Pulido, Guilhem Roubaud, Anne-Laure Cazeau, et al.
Progres En Urologie : Journal De L'Association Francaise D'Urologie Et De La Societe Francaise D'Urologie
|
December 3, 2003
[Upper urinary tract tumor: conservative treatment of localized forms]
Jacques Irani, Fabien Saint, Jean-Louis Bonnal, et al.
Page
of 13